| Resolution of inflammation is altered in Alzheimer's disease X Wang, M Zhu, E Hjorth, V Cortés-Toro, H Eyjolfsdottir, C Graff, ... Alzheimer's & Dementia 11 (1), 40-50. e2, 2015 | 316 | 2015 |
| Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device H Eyjolfsdottir, M Eriksdotter, B Linderoth, G Lind, B Juliusson, P Kusk, ... Alzheimer's research & therapy 8, 1-11, 2016 | 137 | 2016 |
| Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor D Ferreira, E Westman, H Eyjolfsdottir, P Almqvist, G Lind, B Linderoth, ... Journal of Alzheimer's Disease 43 (3), 1059-1072, 2015 | 102 | 2015 |
| Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid CE Hanzel, MF Iulita, H Eyjolfsdottir, E Hjorth, M Schultzberg, ... Journal of Alzheimer's disease 40 (3), 667-678, 2014 | 68 | 2014 |
| Prevalence and clinical characteristics of ankylosing spondylitis in Iceland-a nationwide study AJ Geirsson, H Eyjolfsdottir, G Bjornsdottir, K Kristjansson, ... Clin Exp Rheumatol 28 (3), 333-40, 2010 | 68 | 2010 |
| Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease A Karami, H Eyjolfsdottir, S Vijayaraghavan, G Lind, P Almqvist, A Kadir, ... Alzheimer's & Dementia 11 (11), 1316-1328, 2015 | 67 | 2015 |
| Targeting Alzheimer's disease with gene and cell therapies R Loera‐Valencia, A Piras, MAM Ismail, S Manchanda, H Eyjolfsdottir, ... Journal of Internal Medicine 284 (1), 2-36, 2018 | 58 | 2018 |
| The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study A Machado, D Ferreira, MJ Grothe, H Eyjolfsdottir, PM Almqvist, L Cavallin, ... Alzheimer's Research & Therapy 12, 1-11, 2020 | 45 | 2020 |
| Influence of allergy on immunoglobulins and amyloid-β in the cerebrospinal fluid of patients with Alzheimer’s disease H Sarlus, H Eyjolfsdottir, M Eriksdotter, M Oprica, M Schultzberg Journal of Alzheimer's Disease 48 (2), 495-505, 2015 | 12 | 2015 |
| The cholinergic system and treatment response in subtypes of Alzheimer’s disease A Machado, D Ferreira, MJ Grothe, H Eyjolfsdottir, PM Almqvist, L Cavallin, ... MedRxiv, 2020.01. 23.20018507, 2020 | 10 | 2020 |
| Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second‑generation encap‑sulated cell biodelivery … H Eyjolfsdottir, M Eriksdotter, B Linderoth, G Lind, B Juliusson, P Kusk, ... DOI: https://doi. org/10.1186/s13195-016-0195-9, 30, 0 | 8 | |
| Fast alpha activity in EEG of patients with Alzheimer’s disease is paralleled by changes in cognition and cholinergic markers during Encapsulated cell Biodelivery of nerve … H Eyjolfsdottir, T Koenig, A Karami, P Almqvist, G Lind, B Linderoth, ... Frontiers in aging neuroscience 14, 756687, 2022 | 3 | 2022 |
| Cerebrospinal fluid inflammatory markers in Alzheimer’s disease: influence of comorbidities Y Wang, C Emre, H Gyllenhammar-Schill, K Fjellman, H Eyjolfsdottir, ... Current Alzheimer Research 18 (2), 157-170, 2021 | 3 | 2021 |
| O003/# 714 COGNITIVE RESTORATION IN ALZHEIMER’S PATIENTS BY LOCAL INTRACEREBRAL CELL-MEDIATED NERVE GROWTH FACTOR DELIVERY: CLINICAL EFFICACY AND FURTHER METHOD OPTIMIZATION … B Linderoth, S Mitra, P Almqvist, G Lind, H Eyjolfsdottir, H Behbahani, ... Neuromodulation 25 (7), S33-S34, 2022 | 1 | 2022 |
| Nerve Growth Factor in Alzheimer’s Disease: Biological Effects and Therapeutic Potential H Eyjolfsdottir PQDT-Global, 2017 | 1 | 2017 |
| Materials and methods: NGF-ECB implants were implanted bilaterally in the basal forebrain of six AD patients for 12 months. EEG recordings and quantitative analysis were … H Eyjolfsdottir, T Koenig, A Karami, P Almqvist, G Lind, B Linderoth, ... Oscillatory brain activity as a marker of brain function and dysfunction in …, 2023 | | 2023 |
| The power of genetic knowledge of a population: A lesson from the Generation study 2: Human/Human trials: Anti‐amyloid J Snædal, S Thordardottir, H Eyjolfsdottir, T Gislason Alzheimer's & Dementia 16, e043011, 2020 | | 2020 |
| The power of genetic knowledge of a population, a lesson from the Generation Study 2 J Snædal, S Thordardottir, H Eyjolfsdottir, T Gislason 2020 Alzheimer's Association International Conference, 2020 | | 2020 |
| P. 777 Markers of inflammation and depressive symptoms in the elderly with and without Alzheimer's disease D Enache, D Aarsland, H Eyjolfsdottir, M Schultzberg, M Eriksdotter, ... European Neuropsychopharmacology 29, S520-S521, 2019 | | 2019 |
| P2‐387: NGF CELL THERAPY IN AD PATIENTS: EFFECTS ON CSF CHOLINERGIC BIOMARKERS A Karami, H Eyjolfsdottir, S Vijayaraghavan, G Lind, A Per, A Kadir, ... Alzheimer's & Dementia 10, P620-P620, 2014 | | 2014 |
